WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of ...

The antibody was discovered only in the last few decades, but now we know that it's a different disease entirely because NMO has an antibody. So normally, antibodies are good. Antibodies fight ...

Multiple sclerosis (MS) is a disease marked by focal demyelinating ... Lack of pain Ischemic optic neuropathy, NMO-associated optic neuritis, LHON, Susac syndrome, various maculopathies Disc ...